Allos Therapeutics to Present at Rodman & Renshaw Conference

Allos Therapeutics to Present at Rodman & Renshaw Conference



WESTMINSTER, Colo., Oct. 20  /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc.
(NASDAQ:ALTH) today announced that the Company will participate in Rodman &
Renshaw's Sixth Annual Healthcare Conference, to be held on October 26-28, 2004
in New York City.  Michael E. Hart, President and Chief Executive Officer of
Allos will give a 20-minute corporate overview on Tuesday, October 26 at 12:55
p.m. EST.

The presentation will be webcast live and may be accessed by visiting the Allos
website at http://www.allos.com/.  A replay of the webcast will also be
available on the company's website until Tuesday, November 9, 2004.

About Allos Therapeutics, Inc.

Allos Therapeutics, Inc. is a biopharmaceutical company focused on developing
and commercializing innovative drugs for improving cancer treatments.  The
company's lead clinical candidate, EFAPROXYN(TM), is a synthetic small molecule
that has the potential to sensitize hypoxic (oxygen deprived) tumor tissues and
enhance the efficacy of standard radiation therapy.  In addition, Allos is
developing PDX (pralatrexate), a novel small molecule cytoxic injectable
antifolate (DHFR inhibitor) that is currently being investigated in patients
with non-small cell lung cancer and non- Hodgkin's lymphoma.  For more
information, please visit the company's web site at: http://www.allos.com/. 

DATASOURCE: Allos Therapeutics, Inc.



CONTACT:  Jennifer Neiman Manager, Corporate Communications of Allos

Therapeutics, [phone], 



Web site:  http://www.allos.com/ 

Copyright